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osting by EAbstract A new series of 12 derivatives of 4-pyrazolyl-N-arylquinoline-2,5-dione (4a–l) were
synthesized by one pot base catalyzed cyclocondensation reaction of 1-aryl-5-chloro-3-methyl-
1H-pyrazole-4-carbaldehyde (1a–c), Meldrum’s acid (2) and 3-arylamino-5,5-disubstitutedcyclo-
hex-2-enone (3a–d). All the compounds were characterized by elemental analysis, FT-IR, 1H
NMR and 13C NMR spectral data and were screened, against six bacterial pathogens, namely
Bacillus subtilis, Clostridium tetani, Streptococcus pneumoniae, Salmonella typhi, Vibrio cholerae,
Escherichia coli and antifungal activity, against two fungal pathogens Aspergillus fumigatus and
Candida albicans, using broth microdilution MIC (minimum inhibitory concentration) method.
Some of the compounds were found to be equipotent or more potent than commercial drugs,
against most of the employed strains, as evident from the screening data.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The incidence of fungal and bacterial infections has increased
dramatically in recent years (Peara and Patterson, 2002). The
widespread use of antifungal and antibacterial drugs and their2692 226856; mobile: +91
oo.com (M.P. Patel).
y. Production and hosting by
Saud University.
lsevierresistance against fungal and bacterial infections has led to
serious health hazards. The resistance of wide spectrum anti-
fungal and antibacterial agents has initiated discovery and
modiﬁcation of the new antifungal and antibacterial drugs
(Biot et al., 2000).
The carbostyril (2-quinolone) skeleton is a fertile source of
biologically important molecules possessing a wide spectrum
of biological and pharmacological activities, such as antimi-
crobial (Jayashree et al., 2009; Creaven et al., 2010), antiprolif-
erative (Chen et al., 2007), antithrombotic (Buchanan et al.,
1989), anti-hepatitis B (Cheng et al., 2008), anti-HIV (Zhang
et al., 2003), anti-tumor (Joseph et al., 2002), antioxidative
activity (Chung and Woo, 2001) and cytotoxicity against hu-
man tumor cell lines (He et al., 2005). Several carbostyril deriv-
atives are also nitric oxide production inhibitors (Ito et al.,
2004), 5-HT1B/5-HT2A receptor antagonists (McCort et al.,
2001), Rho-kinase inhibitors (Letellier et al., 2008), androgen
receptors (Oeveren et al., 2007), p38aMAP kinase inhibitors
76 N.J. Thumar, M.P. Patel(Peifer et al., 2008) and induce mitochondrial dysfunction
(Chilin et al., 2005). Therefore, the synthesis of 2-quinolone
derivatives has kindled a strong interest in us.
In recent years, several 4-functionally substituted N-arylpy-
razole derivatives, which have been identiﬁed as antimicrobial
(Damljanovic et al., 2009), anti-inﬂammatory (Bekhit et al.,
2008), antitubercular (Chovatia et al., 2007), antitumor (Jok-
sovic et al., 2009), antiangiogenesis (Abadi et al., 2003), anti-
parasitic (Rathelot et al., 2002), antiviral (Hashem et al.,
2007) also possess analgesic and anxiolytic activities. (Shetty
and Bhagat, 2008).
The classic multicomponent reaction approach for N-
substituted-2-quinolones involves base-catalyzed cyclization
of aldehyde, Meldrum’s acid and b-enaminone. Literature sur-
vey (Wang et al., 2007; Tu et al., 2001, 2006; Suarez et al.,
1999) revealed few studies concerning N-substituted quinolin-
2-one derivatives of aromatic aldehyde, wherein not a single
reference where 1H-pyrazole-4-carbaldehydes are used and
evaluated for their biological proﬁle.
In view of these particulars and by taking into account a
modiﬁcation on the quinolone nucleus can bring signiﬁcant
changes in pharmacological activities and can afford new clas-
ses of therapeutically active compounds for biomedical screen-
ing containing therapeutically active moieties pyrazole and
quinolin-2-one and as part of our current studies in developing
new antimicrobial agents containing quinoline (Ladani et al.,
2009a,b, 2010; Mungra et al., 2009, 2010; Nirmal et al.,
2009; Shah et al., 2009; Thakor et al., 2008) and 1H-pyra-
zole-4-carbaldehyde (Thumar and Patel, 2009a, 2011; Shah
et al., 2009) derivatives, we report herein the synthesis of some
new derivatives of 4-pyrazolyl-N-arylquinoline-2,5-dione (4a–
l) via multicomponent reaction approach. The constitution of
all the products was characterized using elemental analysis,
FT-IR, 1H NMR, 13C NMR and mass spectrometry. All com-
pounds were screened for in vitro antimicrobial activity against
eight human pathogens, of which three were Gram-positive
bacterial pathogens Streptococcus pneumoniae, Clostridium
tetani, Bacillus subtilis, three were Gram-negative bacterial
pathogens Salmonella typhi, Vibrio cholerae, Escherichia coli
and two were fungal pathogens Aspergillus fumigatus and Can-
dida albicans, using broth microdilution MIC method
(NCCLS, 2002; Zanatta et al., 2007).Scheme 1 Synthetic pathway for the intermediate 1-aryl-5-2. Material and methods
2.1. General
Required acetic anhydride, substituted anilines, malonic acid
and phosphorous oxychloride were obtained from S.D. Fine
Chem Ltd., Vadodara, Gujarat, India. Cyclohexanedione and
dimedone were obtained from Sigma–Aldrich. Moreover, 1-
aryl-3-methyl-1H-pyrazol-5(4H)-ones were obtained from
Meghmani Organics Ltd., Ahmedabad, Gujarat, India and
were used without further puriﬁcation. Solvents were puriﬁed
and dried before being used. The microwave assisted reactions
are conducted in a ‘‘RAGA’s Modiﬁed Electromagnetic Micro-
wave System’’ whereby microwaves are generated by magne-
tron at a frequency of 2450 MHz having an adjustable output
power levels, i.e., 10 levels from 140 to 700 W and with an indi-
vidual sensor for temperature control (ﬁber optic is used as aindividual sensor for temperature control) with attachment of
reﬂux condenser with constant stirring (thus avoiding the risk
of high pressure development). All the melting points were
determined in open glass capillary tubes using an electrical
melting point apparatus (IEI Instrumentation Pvt. Ltd., Ahme-
dabad, India) and are uncorrected. Thin-layer chromatography
(TLC), was performed on aluminum plates (precoated with sil-
ica gel, 60F254, 0.25 mm thickness, Merck, Darmstadt, Ger-
many) for monitoring the progress of all reactions, purity and
homogeneity of the synthesized compounds; the solvent system
toluene:ethyl acetate (7:3) was used UV radiation and/or iodine
were used as the visualizing agents. Elemental analysis (% C,
H, N) was carried out by Perkin-Elmer 2400 series-II elemental
analyzer (Perkin-Elmer, USA) and all compounds are within
±0.4% of the calculated value. The IR spectra were recorded
in KBr on a Perkin-Elmer Spectrum GX FT-IR Spectropho-
tometer (Perkin-Elmer, USA) and only the characteristic peaks
are reported in cm1. 1H NMR and 13C NMR spectra were re-
corded in DMSO-d6 on a Bruker Avance 400F (MHz) spec-
trometer (Bruker Scientiﬁc Corporation Ltd., Switzerland)
using solvent peak as internal standard at 400 and 100 MHz,
respectively. Chemical shifts are reported in parts per million
(ppm). Splitting patterns were designated as follows: s, singlet;
d, doublet; dd, doublet of doublet and m, multiplet.
2.2. Chemistry
2.2.1. General procedure for 1-aryl-5-chloro-3-methyl-1H-
pyrazole-4-carbaldehyde (1a–c)
1-Aryl-5-chloro-3-methyl-1H-pyrazole-4-carbaldehyde (1a–c)
were prepared, according to literature procedure (Xiao et al.,
2005), by Vilsmeier–Haack reaction of 1-aryl-3-methyl-1H-
pyrazol-5(4H)-one (Scheme 1).
To ice cold dimethylformamide (0.4 mol) was added drop-
wise with stirring phosphorus oxychloride (0.4 mol) over a per-
iod of 30 min, stirring was continued for further 45 min
keeping the reaction mixture at 0 C. Appropriate 1-aryl-3-
methyl-1H-pyrazol-5(4H)-one (0.08 mol) was then added and
the reaction mixture was allowed to attain room temperature.
The mixture was then heated at 90 C for 4 h, allowed to cool
and poured onto mixture of crushed ice and water. The precip-
itates obtained were ﬁltered, dried and crystallized from etha-
nol to obtain the required 1-aryl-5-chloro-3-methyl-1H-
pyrazole-4-carbaldehyde (1a–c).
2.2.2. General procedure for Meldrum’s acid (2,2-dimethyl-1,3-
dioxane-4,6-dione) (2)
Meldrum’s acid (2,2-dimethyl-1,3-dioxane-4,6-dione) (2) was
synthesized, according to literature method (Davidson and
Bernhard, 1948), by a condensation reaction of malonic acidchloro-3-methyl-pyrazole-4-carbaldehydes (1a–c).
Scheme 2 Synthetic pathway for Meldrum’s acid (2).
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(Scheme 2).
A suspension of powdered malonic acid (0.5 mol) in acetic
anhydride (0.64 mol) was added, while stirring, 1.5 mL of
conc. sulfuric acid. Most of the malonic acid dissolved with
spontaneous cooling. To the resulting solution, acetone
(0.55 mol) was added while cooling to maintain the tempera-
ture at 20–25 C. The reaction mixture was allowed to stand
overnight in the refrigerator and the resulting crystals ﬁltered
by suction and washed three times with sufﬁcient ice water.
Recrystallization was effected without heating by dissolving
10 g of the product in 20 mL of acetone, ﬁltering and adding
40 mL of water to get crystals of Meldrum’s acid (2).
2.2.3. General procedure for 3-arylamino-5,5-(un)
substitutedcyclohex-2-enones (3a–d)
3-Arylamino-5,5-(un)substitutedcyclohex-2-enones (3a–d) were
synthesized, according to literature procedure (Chanda et al.,
2004), by the solid phase reaction of 1,3-dicarbonyl compound
and 4-ﬂuoroaniline under microwave irradiation (Scheme 3).
A reaction mixture of equimolar amount of appropriate 5,5-
disubstitutedcyclohexane-1,3-dione (0.05 mol) and 4-substi-
tutedaniline (0.05 mol) was irradiated in the microwave oven
at 350 W level (50% of the total power) for 9 min (three pulses
each of 3 min). After the completion of the reaction (which was
monitored by TLC), crude product was cooled to room
temperature, dissolved in diethyl ether and the mixture was stir-
red for 15–20 min and ﬁltered. The product was repeatedly
washed with ether and dried, to give 3-(4-arylamino)-5,5-disub-
stitutedcyclohex-2-enone, which were used without further
puriﬁcation.
2.2.4. General procedure for 4-(1-aryl-5-chloro-3-methyl-1H-
pyrazol-4-yl)-1-aryl-7,7-(un)substituted-3,4,7,8-tetrahydro-
quinoline-2,5(1H,6H)-dione (4a–l)
A mixture of 1-aryl-5-chloro-3-methyl-1H-pyrazole-4-carbal-
dehyde (1a–c) (30 mmol), Meldrum’s acid (2) (30 mmol), and
appropriate b-enaminone (3a–d) (30 mmol) in ethanol
(20 mL) containing 3 drops of piperidine was slowly heated
and reﬂuxed with stirring for 6 h. The completion of reaction
was monitored by TLC (ethyl acetate:toluene 3:7). The
reaction mixture was cooled to room temperature and the solid
separated was ﬁltered and washed with a mixture of chloro-
form and methanol (1:1) to obtain the pure compounds 4a–l.Scheme 3 Synthetic pathway for thePhysical and analytical data of the compounds 4a–l are given
in Table 1 and spectroscopic characterization data of the com-
pounds 4a–l are given hereafter:
2.2.4.1. 4-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-(4-
ﬂuorophenyl)-3,4,7,8-tetrahydroquinoline-2,5(1H,6H)-dione
(4a). IR (KBr, m, cm1): 3005 (ArC–H str.), 1705 (C‚O str.),
1650 (cyclic N–C‚O str.), 1185 (ArC–F str.); 1H NMR
(400 MHz, DMSO-d6) dH (ppm): 1.80–2.33 (m, 6H, 3·CH2),
2.36 (s, 3H, CH3), 2.64 (d, J= 16.8 Hz, 1H, H3), 3.04 (dd,
J= 16.4 Hz, J0 = 8.0 Hz, 1H, H3), 4.36 (d, J= 8.8 Hz, 1H,
H4), 6.94–7.98 (m, 9H, Ar–H); 13C NMR (100 MHz,
DMSO-d6) dC (ppm): 12.86 (CH3), 21.38 (C8), 26.88 (C4),
28.58 (C7), 36.66 (C3), 38.61 (C6), 111.93, 114.99, 117.70,
122.09, 123.73, 127.25, 130.90, 133.92, 136.19, 142.83, 145.35,
153.55, 155.04 (Ar–C), 169.53 (C2), 196.14 (C5).
2.2.4.2. 4-(5-Chloro-1-(3-chlorophenyl)-3-methyl-1H-pyrazol-
4-yl)-1-(4-ﬂuorophenyl)-3,4,7,8-tetrahydroquinoline-2,5(1H,6H)-
dione (4b). IR (KBr, m, cm1): 3010 (ArC–H str.), 1695 (C‚O
str.), 1640 (cyclic N–C‚O str.), 1170 (ArC–F str.); 1H NMR
(400 MHz, DMSO-d6) dH (ppm): 1.85–2.24 (m, 6H,
3 · CH2), 2.32 (s, 3H, CH3), 2.65 (d, J= 16.0 Hz, 1H, H3),
3.13 (dd, J= 15.6 Hz, J0 = 7.2 Hz, 1H, H3), 4.53 (d,
J= 7.6 Hz, 1H, H4), 6.99–7.85 (m, 8H, Ar–H); 13C NMR
(100 MHz, DMSO-d6) dC (ppm): 12.77 (CH3), 22.49 (C8),
27.38 (C4), 28.45 (C7), 37.36 (C3), 38.82 (C6), 111.80,
113.17, 115.69, 116.34, 121.52, 124.50, 128.12, 131.42, 134.72,
144.03, 146.60, 149.61, 154.84, 155.81, 157.20 (Ar–C), 168.24
(C2), 195.56 (C5).
2.2.4.3. 4-(5-Chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-1-(4-
ﬂuorophenyl)-3,4,7,8-tetrahydroquinoline-2,5(1H,6H)-dione
(4c). IR (KBr, m, cm1): 3000 (ArC–H str.), 1715 (C‚O str.),
1650 (cyclic N–C‚O str.), 1200 (ArC–F str.); 1H NMR
(400 MHz, DMSO-d6) dH (ppm): 1.75–2.19 (m, 6H, 3·CH2),
2.25 (s, 3H, pyz-CH3), 2.35 (s, 3H, tolyl–CH3), 2.71 (d,
J= 15.2 Hz, 1H, H3), 3.12 (dd, J= 16.8 Hz, J0 = 7.2 Hz,
1H, H3), 4.45 (d, J= 8.0 Hz, 1H, H4), 7.04–8.17 (m, 8H,
Ar–H); 13C NMR (100 MHz, DMSO-d6) dC (ppm): 12.85
(pyz–CH3), 21.03 (tolyl–CH3), 22.80 (C8), 27.22 (C4), 28.37
(C7), 36.38 (C3), 37.90 (C6), 112.23, 113.86, 118.46, 124.53,
127.01, 128.68, 129.36, 132.26, 133.71, 136.63, 145.14, 152.59,
155.08 (Ar–C), 168.44 (C2), 197.05 (C5).
2.2.4.4. 4-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-
(4-ﬂuorophenyl)-7,7-dimethyl-3,4,7,8-tetrahydroquinoline-2,
5(1H,6H)-dione (4d). IR (KBr, m, cm1): 3005 (ArC–H str.),
1690 (C‚O str.), 1660 (cyclic N–C‚O str.), 1210 (ArC–F
str.); 1H NMR (400 MHz, DMSO-d6) dH (ppm): 0.80 (s, 3H,
CH3), 0.94 (s, 3H, CH3), 1.86–2.25 (m, 4H, 2·CH2), 2.31 (s,
3H, CH3), 2.78 (d, J= 16.0 Hz, 1H, H3), 3.26 (dd,intermediate enaminones (3a–d).
Table 1 Physical and analytical characterization data of compounds 4a–l.
Compound Yield (%) m.p. (C.) Mol. formula (Mol. Wt.) Elemental analysis (%), Found (Calcd.)
C H N
4a 68 234–235 C25H21ClFN3O2 (449.90) 67.06 (66.74) 5.02 (4.70) 9.19 (9.34)
4b 72 202–204 C25H20Cl2FN3O2 (484.35) 62.28 (61.99) 3.95 (4.16) 9.04 (8.68)
4c 66 221–223 C26H23ClFN3O2 (463.93) 66.96 (67.31) 5.27 (5.00) 8.85 (9.06)
4d 70 243–245 C27H25ClFN3O2 (477.96) 68.03 (67.85) 4.92 (5.27) 9.06 (8.79)
4e 65 177–180 C27H24Cl2FN3O2 (512.40) 62.04 (63.29) 5.02 (4.72) 7.91 (8.20)
4f 60 218–221 C28H27ClFN3O2 (491.98) 68.00 (68.36) 5.77 (5.53) 8.87 (8.54)
4g 65 250–253 C26H24ClN3O3 (461.94) 67.81 (67.60) 4.95 (5.24) 8.83 (9.10)
4h 55 186–188 C26H23Cl2N3O3 (496.39) 63.28 (62.91) 4.40 (4.67) 8.61 (8.47)
4i 65 222–224 C27H26ClN3O3 (475.97) 67.89 (68.13) 5.72 (5.51) 9.13 (8.83)
4j 58 239–241 C28H28ClN3O3 (489.99) 68.82 (68.63) 5.59 (5.76) 8.31 (8.58)
4k 70 191–192 C28H27Cl2N3O3 (524.44) 63.84 (64.13) 5.30 (5.19) 7.88 (8.01)
4l 72 215–216 C29H30ClN3O3 (504.02) 68.82 (69.11) 5.85 (6.00) 8.56 (8.34)
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H4), 7.02–7.86 (m, 9H, Ar–H); 13C NMR (100 MHz,
DMSO-d6) dC (ppm): 12.61 (pyz–CH3), 26.53, 26.86 (CH3),
27.93 (C4), 32.36 (C7), 38.43 (C6), 42.08 (C8), 51.97 (C3),
112.16, 115.74, 117.37, 124.54, 125.11, 129.43, 132.21, 134.27,
135.06, 138.49, 144.31, 153.58, 156.47 (Ar–C), 169.62 (C2),
195.14 (C5).
2.2.4.5. 4-(5-Chloro-1-(3-chlorophenyl)-3-methyl-1H-pyrazol-
4-yl)-1-(4-ﬂuorophenyl)-7,7-dimethyl-3,4,7,8-tetrahydroquino-
line-2,5(1H,6H)-dione (4e). IR (KBr, m, cm1): 3010 (ArC–H
str.), 1700 (C‚O str.), 1645 (cyclic N–C‚O str.), 1200 (ArC–
F str.); 1H NMR (400 MHz, DMSO-d6) dH (ppm): 0.88 (s, 3H,
CH3), 0.92 (s, 3H, CH3), 1.94–2.32 (m, 4H, 2·CH2), 2.35 (s,
3H, CH3), 2.83 (d, J= 16.4 Hz, 1H, H3), 3.10 (dd,
J= 16.0 Hz, J0 = 8.4 Hz, 1H, H3), 4.49 (d, J= 7.2 Hz, 1H,
H4), 7.05–8.21 (m, 8H, Ar–H); 13C NMR (100 MHz,
DMSO-d6) dC (ppm): 12.57 (pyz–CH3), 26.18, 27.12 (CH3),
28.86 (C4), 32.13 (C7), 37.45 (C6), 41.56 (C8), 52.72 (C3),
112.96, 114.97, 119.94, 122.55, 123.23, 128.65, 130.28, 134.79,
136.02, 139.44, 142.87, 143.38, 147.79, 153.85, 156.32 (Ar–C),
169.16 (C2), 195.63 (C5).
2.2.4.6. 4-(5-Chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-1-
(4-ﬂuorophenyl)-7,7-dimethyl-3,4,7,8-tetrahydroquinoline-2,
5(1H,6H)-dione (4f). IR (KBr, m, cm1): 3015 (ArC–H str.),
1715 (C‚O str.), 1665 (cyclic N–C‚O str.), 1185 (ArC–F
str.); 1H NMR (400 MHz, DMSO-d6) dH (ppm): 0.90 (s, 3H,
CH3), 1.03 (s, 3H, CH3), 1.84–2.21 (m, 4H, 2·CH2), 2.32 (s,
3H, pyz–CH3), 2.37 (s, 3H, tolyl–CH3), 2.67 (d, J= 15.6 Hz,
1H, H3), 3.19 (dd, J= 16.8 Hz, J0 = 8.0 Hz, 1H, H3), 4.53
(d, J= 7.6 Hz, 1H, H4), 6.95–8.03 (m, 8H, Ar–H); 13C
NMR (100 MHz, DMSO-d6) dC (ppm): 12.50 (pyz–CH3),
20.98 (tolyl–CH3), 25.62, 26.24 (CH3), 27.99 (C4), 31.21
(C7), 38.64 (C6), 39.75 (C8), 52.16 (C3), 113.45, 116.75,
118.56, 120.15, 125.29, 128.66, 132.22, 137.78, 140.67, 145.07,
148.89, 153.39, 155.40 (Ar–C), 169.13 (C2), 196.37 (C5).
2.2.4.7. 4-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-(4-
methoxyphenyl)-3,4,7,8-tetrahydroquinoline-2,5(1H,6H)-dione
(4g). IR (KBr, m, cm1): 3025 (ArC–H str.), 1705 (C‚O str.),
1655 (cyclic N–C‚O str.), 1215 and 1065 (asym. and sym. str.
of ArC–OMe), 1175 (ArC–F str.); 1H NMR (400 MHz,
DMSO-d6) dH (ppm): 1.90–2.22 (m, 6H, 3·CH2), 2.37 (s, 3H,CH3), 2.67 (d, J= 15.2 Hz, 1H, H3), 3.19 (dd, J= 15.6 Hz,
J0 = 7.2 Hz, 1H, H3), 3.72 (s, 3H, OCH3), 4.31 (d,
J= 8.8 Hz, 1H, H4), 6.81–7.88 (m, 9H, Ar–H); 13C NMR
(100 MHz, DMSO-d6) dC (ppm): 12.62 (CH3), 21.78 (C8),
26.96 (C4), 27.58 (C7), 36.57 (C3), 38.85 (C6), 55.80 (OCH3),
113.19, 115.02, 117.65, 124.24, 125.40, 128.57, 129.58, 130.16,
131.00, 138.27, 148.23, 157.10, 159.42 (Ar–C), 168.76 (C2),
196.98 (C5).
2.2.4.8. 4-(5-Chloro-1-(3-chlorophenyl)-3-methyl-1H-pyrazol-
4-yl)-1-(4-methoxyphenyl)-3,4,7,8-tetrahydroquinoline-2,
5(1H,6H)-dione (4h). IR (KBr, m, cm1): 3015 (ArC–H str.),
1690 (C‚O str.), 1650 (cyclic N–C‚O str.), 1230 and 1075
(asym. and sym. str. of ArC–OMe), 1205 (ArC–F str.); 1H
NMR (400 MHz, DMSO-d6) dH (ppm): 1.72–2.20 (m, 6H,
3·CH2), 2.27 (s, 3H, CH3), 2.63 (d, J= 16.0 Hz, 1H, H3),
3.06 (dd, J= 16.4 Hz, J0 = 8.8 Hz, 1H, H3), 3.85 (s, 3H,
OCH3), 4.44 (d, J= 8.0 Hz, 1H, H4), 6.93–8.07 (m, 8H, Ar–
H); 13C NMR (100 MHz, DMSO-d6) dC (ppm): 12.88 (CH3),
21.67 (C8), 27.37 (C4), 27.12 (C7), 36.41 (C3), 38.56 (C6),
55.78 (OCH3), 114.14, 115.53, 118.59, 120.87, 121.42, 123.58,
126.07, 130.18, 130.62, 136.20, 138.75, 141.21, 149.39, 153.92,
155.43 (Ar–C), 170.27 (C2), 197.23 (C5).
2.2.4.9. 4-(5-Chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-1-(4-
methoxyphenyl)-3,4,7,8-tetrahydroquinoline-2,5(1H,6H)-dione
(4i). IR (KBr, m, cm1): 3000 (ArC–H str.), 1710 (C‚O str.),
1645 (cyclic N–C‚O str.), 1245 and 1055 (asym. and sym. str.
of ArC–OMe), 1170 (ArC–F str.); 1H NMR (400 MHz,
DMSO-d6) dH (ppm): 1.79–2.31 (m, 6H, 3·CH2), 2.37 (s, 3H,
pyz–CH3), 2.41 (s, 3H, tolyl–CH3), 2.75 (d, J= 15.6 Hz, 1H,
H3), 3.27 (dd, J= 15.2 Hz, J0 = 8.4 Hz, 1H, H3), 3.79 (s,
3H, OCH3), 4.47 (d, J= 8.4 Hz, 1H, H4), 7.08–7.99 (m, 8H,
Ar–H); 13C NMR (100 MHz, DMSO-d6) dC (ppm): 12.73
(pyz–CH3), 21.06 (tolyl–CH3), 22.03 (C8), 27.33 (C4), 28.23
(C7), 36.48 (C3), 38.50 (C6), 55.81 (OCH3), 113.68, 117.62,
118.24, 121.46, 122.33, 127.91, 127.36, 132.29, 137.66, 139.62,
146.17, 150.30, 154.45 (Ar–C), 168.85 (C2), 196.79 (C5).
2.2.4.10. 4-(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-
(4-methoxyphenyl)-7,7-dimethyl-3,4,7,8-tetrahydroquinoline-
2,5(1H,6H)-dione (4j). IR (KBr, m, cm1): 3010 (ArC–H str.),
1695 (C‚O str.), 1655 (cyclic N–C‚O str.), 1210 and 1060
(asym. and sym. str. of ArC–OMe), 1175 (ArC–F str.); 1H
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(s, 3H, CH3), 1.88–2.17 (m, 4H, 2·CH2), 2.29 (s, 3H, CH3),
2.67 (d, J= 16.8 Hz, 1H, H3), 3.21 (dd, J= 16.0 Hz,
J0 = 7.6 Hz, 1H, H3), 3.75 (s, 3H, OCH3), 4.30 (d,
J= 7.2 Hz, 1H, H4), 7.02–7.94 (m, 9H, Ar–H); 13C NMR
(100 MHz, DMSO-d6) dC (ppm): 12.69 (pyz–CH3), 25.39,
26.01 (CH3), 28.32 (C4), 31.02 (C7), 38.90 (C6), 41.99 (C8),
51.73 (C3), 55.84 (OCH3), 112.94, 113.72, 114.53, 122.35,
128.37, 129.26, 132.15, 134.27, 135.80, 143.06, 149.54, 151.74,
158.05 (Ar–C), 170.98 (C2), 195.20 (C5).
2.2.4.11. 4-(5-Chloro-1-(3-chlorophenyl)-3-methyl-1H-pyrazol-
4-yl)-1-(4-methoxyphenyl)-7,7-dimethyl-3,4,7,8-tetrahydro-
quinoline-2,5(1H,6H)-dione (4k). IR (KBr, m, cm1): 3000
(ArC–H str.), 1700 (C‚O str.), 1660 (cyclic N–C‚O str.),
1250 and 1020 (asym. and sym. str. of ArC–OMe), 1180
(ArC–F str.); 1H NMR (400 MHz, DMSO-d6) dH (ppm):
0.88 (s, 3H, CH3), 0.96 (s, 3H, CH3), 1.82–2.30 (m, 4H,
2·CH2), 2.38 (s, 3H, CH3), 2.72 (d, J= 16.4 Hz, 1H, H3),
3.08 (dd, J= 15.6 Hz, J0 = 8.0 Hz, 1H, H3), 3.82 (s, 3H,
OCH3), 4.35 (d, J= 8.8 Hz, 1H, H4), 6.90–7.91 (m, 8H, Ar–
H); 13C NMR (100 MHz, DMSO-d6) dC (ppm): 12.54 (pyz–
CH3), 26.05, 27.77 (CH3), 28.14 (C4), 33.24 (C7), 37.55 (C6),
40.24 (C8), 50.83 (C3), 55.71 (OCH3), 113.43, 114.85, 115.64,
120.29, 126.18, 127.76, 133.47, 135.45, 136.25, 139.76, 141.98,
143.81, 146.10, 152.48, 154.31 (Ar–C), 169.39 (C2), 196.41
(C5).
2.2.4.12. 4-(5-Chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-1-
(4-methoxyphenyl)-7,7-dimethyl-3,4,7,8-tetrahydroquinoline-
2,5(1H,6H)-dione (4l). IR (KBr, m, cm1): 3005 (ArC–H str.),
1710 (C‚O str.), 1640 (cyclic N–C‚O str.), 1240 and 1040
(asym. and sym. str. of ArC–OMe), 1175 (ArC–F str.); 1HTable 2 Antimicrobial activity of the compounds 4a–l.
Compounds Minimum inhibitory concentration (MIC, lg/mL)
Gram-positive bacteria Gram-ne
S. p. C. t. B. s. S. t.
MTCC (1936) MTCC (449) MTCC (441) MTCC (9
4a 250 200 500 250
4b 100 1000 100 250
4c 250 100 250 150
4d 500 100 200 200
4e 200 200 200 500
4f 200 500 200 500
4g 50 500 250 100
4h 500 100 500 250
4i 500 250 100 100
4j 250 200 500 500
4k 500 200 500 100
4l 500 250 100 1000
Ampi. 100 250 250 100
Chlora. 50 50 50 50
Cipro. 50 100 50 25
Genta. 0.5 5 1 5
Grise. – – – –
Nyst. – – – –
Ampi.: ampicillin; Chlora.: chloramphenicol; Cipro.: ciproﬂoxacin; Gent
S. p.: Streptococcus pneumoniae; C. t.: Clostridium tetani; B. s.: Bacillus su
coli; A. f.: Aspergillus fumigatus; C. a.: Candida albicans.NMR (400 MHz, DMSO-d6) dH (ppm): 1.03 (s, 3H, CH3),
1.05 (s, 3H, CH3), 1.89–2.23 (m, 4H, 2·CH2), 2.35 (s, 3H,
pyz–CH3), 2.40 (s, 3H, tolyl–CH3), 2.60 (d, J= 16.0 Hz, 1H,
H3), 3.19 (dd, J= 16.4 Hz, J0 = 7.6 Hz, 1H, H3), 3.76 (s,
3H, OCH3), 4.41 (d, J= 8.0 Hz, 1H, H4), 6.91–8.03 (m, 8H,
Ar–H); 13C NMR (100 MHz, DMSO-d6) dC (ppm): 12.65
(pyz–CH3), 20.94 (tolyl–CH3), 25.93, 26.40 (CH3), 27.35
(C4), 32.32 (C7), 38.10 (C6), 40.81 (C8), 49.68 (C3), 55.85
(OCH3), 112.01, 114.87, 115.90, 121.13, 125.57, 126.98,
129.00, 135.12, 138.98, 140.63, 141.90, 152.02, 157.39 (Ar–C),
169.01 (C2), 196.82 (C5).
2.3. Antimicrobial screening
The in vitro antimicrobial activity of all the compounds and
standard drugs were assessed against three representatives of
Gram-positive bacteria viz. S. pneumoniae (MTCC 1936), C.
tetani (MTCC 449), B. subtilis (MTCC 441), three Gram-neg-
ative bacteria viz. S. typhi (MTCC 98), V. cholerae (MTCC
3906), E. coli (MTCC 443) and two fungi viz. A. fumigatus
(MTCC 3008) and C. albicans (MTCC 227) by the Broth Mic-
rodilution MIC method according to National Committee for
Clinical Laboratory Standards (NCCLS). The strains em-
ployed for the activity were procured from (MTCC – Micro-
Type Culture Collection) Institute of Microbial Technology,
Chandigarh. Mueller Hinton Broth was used as a nutrient
medium to grow and dilute the compound suspension for the
test bacteria and Sabouraud Dextrose Broth was used for fun-
gal nutrition. Ampicillin, chloramphenicol, ciproﬂoxacin, gen-
tamicin and norﬂoxacin were used as standard antibacterial
drugs, whereas griseofulvin and nystatin were used as standard
antifungal drugs.gative bacteria Fungi
V. c. E. c. A. f. C. a.
8) MTCC (3906) MTCC (443) MTCC (3008) MTCC (227)
250 100 1000 1000
1000 100 500 1000
50 100 500 500
500 100 1000 1000
500 100 500 1000
500 200 500 1000
1000 50 1000 500
150 500 1000 1000
250 200 500 500
250 100 1000 1000
250 200 1000 500
500 500 1000 1000
100 100 – –
50 50 – –
25 25 – –
5 0.05 – –
– – 100 500
– – 100 100
a.: gentamicin; Grise.: griseofulvin; Nyst.: nystatin.
btilis; S. t.: Salmonella typhi; V. c.: Vibrio cholerae; E. c.: Escherichia
80 N.J. Thumar, M.P. PatelBacterial strains were primarily inoculated into Mueller–
Hinton agar for overnight growth. A number of colonies were
directly suspended in saline solution until the turbidity
matched the turbidity of the McFarland standard (approxi-
mately 108 CFU mL1), i.e., inoculum size for test strain was
adjusted to 108 CFU mL1 (Colony Forming Unit per millili-
ter) per well by comparing the turbidity (turbidimetric meth-
od). Similarly, fungi were inoculated on Sabouraud Dextrose
Broth and the procedures of inoculum standardization were
similar. DMSO was used as diluents/vehicle to get desired con-
centration of the synthesized compounds and standard drugs
to test upon standard microbial strains, i.e., the compounds
were dissolved in DMSO and the solutions were diluted with
a culture medium. Each compound and standard drugs were
diluted obtaining 2000 lg/mL concentration, as a stock solu-
tion. By further progressive dilutions with the test medium,
the required concentrations were obtained for primary and sec-
ondary screening. In primary screening 1000, 500 and 250 lg/
mL concentrations of the synthesized compounds were tested.
The active compounds found in this primary screening were
further diluted to obtain 200, 100, 62.5, 50, 25, 12.5 and
6.250 lg/mL concentrations for secondary screening to test
in a second set of dilution against all microorganisms. Brieﬂy,
the control tube containing no antibiotic is immediately sub
cultured [before inoculation] by spreading a loopful evenly
over a quarter of plate of medium suitable for the growth of
the tested organism. The tubes are then put for incubation at
37 C for 24 h for bacteria and 48 h for fungi. Growth or a lack
of growth in the tubes containing the antimicrobial agent was
determined by comparison with the growth control, indicated
by turbidity. The lowest concentration that completely inhib-
ited visible growth of the organism was recorded as the mini-
mal inhibitory concentration (MIC, lg/mL), i.e., the amount
of growth from the control tube before incubation (which rep-
resents the original inoculum) is compared. A set of tubes con-
taining only seeded broth and the solvent controls were
maintained under identical conditions so as to make sure that
the solvent had no inﬂuence on strain growth. The result of
this is much affected by the size of the inoculum. The test mix-
ture should contain 108 CFU mL1 organisms. The interpreta-Scheme 4 Synthetic pathway for the synthesis otion of the results was based on griseofulvin and nystatin
breakpoints for the fungi and also on ampicillin, chloramphen-
icol, ciproﬂoxacin, gentamicin and norﬂoxacin for bacterial
pathogens. The protocols were summarized in Table 2 as the
minimal inhibitory concentration (MIC, lg/mL).3. Results and discussion
3.1. Chemistry
Vilsmeier–Haack reaction of 1-aryl-3-methyl-1H-pyrazol-
5(4H)-one lead to chloroformylation to give required 1-aryl-
5-chloro-3-methyl-1H-pyrazole-4-carbaldehyde (1a–c) (Xiao
et al., 2005) (Scheme 1). Moreover, Meldrum’s acid (2,2-di-
methyl-1,3-dioxane-4,6-dione) (2) was synthesized (Davidson
and Bernhard, 1948) by a condensation reaction of malonic
acid with acetone in acetic anhydride with sulfuric acid at
0 C (Scheme 2). The required b-enaminones (3a–d) were syn-
thesized, according to literature procedure (Chanda et al.,
2004), by the solid phase reaction of 1,3-dicarbonyl compound
and 4-ﬂuoroaniline under microwave irradiation (Scheme 3).
In continuation of our interest on synthesizing biologically
active heterocyclic derivatives (Ladani et al., 2009a,b, 2010;
Mungra et al., 2009, 2010; Nirmal et al., 2009; Shah et al.,
2009; Thumar and Patel, 2009a,b, 2011; Thakor et al., 2008),
we report herein a new series of 4-pyrazolyl-N-arylquinoline-
2,5-dione (4a–l) derivatives which were synthesized by one
pot three component cyclocondensation reaction of 1-aryl-5-
chloro-3-methyl-1H-pyrazole-4-carbaldehyde (1a–c), Mel-
drum’s acid (2) and 3-arylamino-5,5-disubstitutedcyclohex-2-
enone (3a–d) (Scheme 4).
Trials to obtain the title 4H-quinolone derivatives (4a–l),
following the reported procedures, when the reaction was car-
ried out in aqueous media under neutral conditions failed to
proceed even on prolong reﬂuxing. The reaction was then tried
under microwave irradiation, without any success. When the
reaction proceeded under basic conditions such as pyridine,
morpholine, K2CO3 and DMAP, under reﬂux for a long timef carbostyril derivatives of 1H-pyrazole (4a–l).
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ethanol for 6 h in the presence of piperidine as basic catalyst
gave moderate to good yield (58–72%) (Scheme 4). Hence,
these conditions were considered as the most optimized condi-
tions for the synthesis of title derivatives 4H-quinolone deriv-
atives (4a–l).
The structures of all the new compounds were established
by 1H NMR, 13C NMR and FT-IR spectrometry. 1H NMR
(DMSO-d6) spectrum of compounds 4a–l exhibited doublet
around d 4.30–4.54 for methine (H4) and doublet around d
2.60–2.83 and doublet of doublet around d 3.04–3.27 ppm
stands for methylene protons (H3) of the quinolone ring,
respectively. Aromatic protons resonate as multiplets at
around d 6.81–8.21 ppm of quinolone derivatives (4a–l). The
13C NMR spectrum of compounds 4a–l showed a signal
around d 26.88–28.86 and d 36.38–52.72 ppm standing for
methine (C4) and methylene carbon (C3) of quinolone ring,
respectively. The distinctive peaks at d 168.24–170.98 ppm
(C2) and 195.14–197.23 ppm (C5) are assigned to carbonyl car-
bons of quinolone ring. All the aromatic carbons showed sig-
nals around d 111.93–159.42 ppm in the 13C NMR spectra
conﬁrming the structure 4a–l. The IR spectrum of compounds
4a–l exhibited characteristic absorption band around 1715–
1690 and 1665–1640 cm1 for both carbonyl (C‚O) func-
tional group of carbostyril skeleton, respectively. The obtained
elemental analysis values are in good agreement with theoret-
ical data. Similarly, all the compounds were characterized on
the basis of spectral studies. Physical, analytical and spectro-
scopic characterization data of the synthesized 4a–l derivatives
are given in Section 2. All the compounds were screened for
their antibacterial and antifungal activity.
3.2. Antimicrobial screening
The examination of the data (Table 2) reveals that most of the
compounds showed antibacterial and antifungal activity when
compared with standard drugs ampicillin and griseofulvin.
Compounds 4c (R = 4-Me, R1 = H, R2 = F), 4g (R = H,
R1 = H, R2 = OMe) and 4i (R = 4-Me, R1 = H,
R2 = OMe) were found to be highly potent against most of
the employed strains to inhibit the growth of organism. In par-
ticular, compounds 4g (R = H, R1 = H, R2 = OMe) were
found to be more efﬁcient (MIC < 100 lg/mL), whereas 4b
(R = 3-Cl, R1 = H, R2 = F) exhibited comparable activity
to ampicillin against S. pneumoniae (MIC = 100 lg/mL).
The compounds 4a (R = H, R1 = H, R2 = F), 4c (R = 4-
Me, R1 = H, R2 = F), 4d (R = H, R1 =Me, R2 = F), 4e
(R = 3-Cl, R1 =Me, R2 = F), 4h (R = 3-Cl, R1 = H,
R2 = OMe), 4j (R = H, R1 =Me, R2 = OMe) and 4k
(R = 3-Cl, R1 =Me, R2 = OMe) were found to be more efﬁ-
cient (MIC < 250 lg/mL), whereas 4i (R = 4-Me, R1 = H,
R2 = OMe) and 4l (R = 4-Me, R1 =Me, R2 = OMe) were
found equally potent to ampicillin, towards C. tetani
(MIC = 250 lg/mL). The compounds 4b (R = 3-Cl,
R1 = H, R2 = F), 4d (R = H, R1 =Me, R2 = F), 4e
(R = 3-Cl, R1 =Me, R2 = F), 4f, 4i (R = 4-Me, R1 = H,
R2 = OMe) and 4l (R = 4-Me, R1 =Me, R2 = OMe) show
better activity (MIC < 250 lg/mL), whereas 4c (R = 4-Me,
R1 = H, R2 = F) and 4g (R = H, R1 = H, R2 = OMe) were
found equally potent, to ampicillin, against B. subtilis
(MIC = 250 lg/mL). Towards Gram-negative strain S. typhi,compounds 4g (R = H, R1 = H, R2 = OMe), 4i (R = 4-
Me, R1 = H, R2 = OMe) and 4k (R = 3-Cl, R1 =Me,
R2 = OMe) were equally active to ampicillin (MIC =
100 lg/mL). The compounds 4c (R = 4-Me, R1 = H,
R2 = F) were found to exhibit better activity than ampicillin
against V. cholerae. The compound 4g (R = H, R1 = H,
R2 = OMe) shows better (MIC < 100 lg/mL) and 4a (R =
H, R1 = H, R2 = F), 4b (R = 3-Cl, R1 = H, R2 = F), 4c
(R = 4-Me, R1 = H, R2 = F), 4d (R = H, R1 =Me,
R2 = F), 4e (R = 3-Cl, R1 =Me, R2 = F) and 4j (R = H,
R1 =Me, R2 = OMe) were found to exhibit comparable
activity to ampicillin towards E. coli (MIC < 100 lg/mL).
Against fungal pathogen C. albicans, compound 4c (R = 4-
Me, R1 = H, R2 = F), 4g (R = H, R1 = H, R2 = OMe), 4i
(R = 4-Me, R1 = H, R2 = OMe) and 4k (R = 4-Me,
R1 =Me, R2 = OMe) were found to be equipotent compared
to the standard griseofulvin (MIC = 500 lg/mL). None of the
tested compounds was found to be potent against fungal strain
A. fumigatus. The remaining compounds showed moderate to
good activity to inhibit the growth of microbial pathogens and
are all less effective than standard drugs.
The investigation of the structure–activity relationship of
antibacterial screening revealed that the compounds (4c–e)
with p-ﬂuorophenyl at the 1-position of the quinoline nucleus
gave better results against C. tetani, B. subtilis and E. coli. Sim-
ilarly, towards C. tetani, compounds (4h–l) with p-methoxy-
phenyl substituent at the 1-position of the nucleus were
found to be highly active. Against C. tetani, B. subtilis and
E. coli, compounds (4b, 4e, 4h and 4k) containing chloro
substituted phenyl ring in pyrazole were found to be more po-
tent. Compounds (4c, 4f, 4i and 4l) with methyl substituted
phenyl ring in pyrazole have exhibited better activity against
C. tetani and B. subtilis. Similarly, unsubstituted phenyl ring
is found to be active against C. tetani and E. coli. Antifungal
evaluation results revealed none of the effect of the presence
of particular group.
From antimicrobial screening results, it is interesting to
note that a minor alteration in the molecular conﬁguration
of the investigated compounds may have a pronounced effect
on antimicrobial activity.
4. Conclusion
A new series of substituted 4-pyrazolyl-N-arylquinoline-2,5-
dione (4a–l) derivatives has been synthesized via multi compo-
nent reaction approach and characterized through elemental
and spectral analysis. This synthetic strategy allows the con-
struction of relatively complicated nitrogen containing fused
heterocyclic system as well as the introduction of various (het-
ero)aromatic substitutions into 1 and 4-position of quinoline
system. It can be concluded from antimicrobial screening (Ta-
ble 2), against panel of human pathogens that most of the syn-
thesized quinoline derivatives were found to be active,
compared to the standard drugs, against bacterial pathogens.
Among them, many compounds were found to be the most ac-
tive against B. subtilis, C. tetani and E. coli compared to the
rest of the employed species. Antifungal activity of the com-
pounds shows that most of the compounds were found to be
potent against C. albicans compared to A. fumigatus. It is
worth mentioning that minor changes in molecular conﬁgura-
tion of these compounds profoundly inﬂuence the activity.
82 N.J. Thumar, M.P. PatelFurther synthetic modiﬁcation is required to enhance the po-
tency of carbostyril derivatives by changing molecular conﬁg-
uration, which is in progress at our laboratory. The present
study throws light on the identiﬁcation of this new structural
class as antimicrobials which can be of interest for further de-
tailed preclinical investigations.Acknowledgments
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